Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund
Sectoral-PharmaVery HighOPEN-ENDED
- NAV as on 25 Sep 2026
- ₹24.18-0.24%1 day
- Return since launch
- 16.1%
- 52-week range
- ₹19.35 — ₹24.38
- AUM
- ₹200 Cr
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund is a Sectoral-Pharma equity fund from Edelweiss Mutual Fund with ₹200 Cr under management, launched in 2020. Over three years it has returned 17.1% a year, against 21.1% for its category. The expense ratio is 1.10% and the SEBI riskometer reading is Very High.
Performance
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund NAV and returns
Growth of the fund against its category average over the period you pick.
Over 1Y this fund returned +25.0% against +19.5% for its category.
Performance
Returns
How the fund has done against its category and its benchmark.
| Period | Fund | vs category | Category | Benchmark |
|---|---|---|---|---|
| 1Y | 25.2% | +4.3 pts | 20.9% | 26.4% |
| 2Y | 17.7% | +0.9 pts | 16.8% | 15.2% |
| 3Y | 17.1% | −4.0 pts | 21.1% | 15.8% |
| 5Y | 17.8% | +3.5 pts | 14.3% | 18.0% |
| Period | Fund | vs category | Category | Benchmark |
|---|---|---|---|---|
| 1M | -0.3% | −0.4 pts | 0.2% | -0.3% |
| 3M | 5.1% | −1.1 pts | 6.2% | 6.0% |
| 6M | 17.9% | −4.2 pts | 22.1% | 20.9% |
| 1Y | 25.0% | +4.1 pts | 20.9% | 19.5% |
| 2Y | 9.3% | +1.1 pts | 8.2% | 6.5% |
| 3Y | 20.0% | −1.2 pts | 21.1% | 20.1% |
| 5Y | 13.9% | −0.4 pts | 14.3% | 13.4% |
Since launch (6 Oct 2020): 16.1%
Calendar-year returns
Category average18.0%
-5.3%
24.4%
28.6%
4.9%
Show as a table
| Period | Fund | vs category | Category |
|---|---|---|---|
| 2025 | 4.9% | +6.9 pts | -2.0% |
| 2024 | 28.6% | −12.3 pts | 40.9% |
| 2023 | 24.4% | −11.8 pts | 36.2% |
| 2022 | -5.3% | +3.0 pts | -8.3% |
| 2021 | 18.0% | −3.7 pts | 21.7% |
Returns over one year are annualised. Shorter periods are absolute.
Costs & terms
Costs and terms
What the fund charges each year, and the rules around putting money in and taking it out.
Costs
1.10%
Expense ratio as on 25 Sep 2026
Charged yearly and already deducted from the NAV.
- Base expense
- 0.90%
- Brokerage
- 0.01%
- Transaction charges
- 0.00%
- Statutory levies
- 0.19%
- Exit load
- 0%
- Lock-in
- None
Terms
- Min SIP
- ₹-1
- Min lumpsum
- ₹-1
- Plan
- GROWTH
- Fund type
- OPEN-ENDED
- Benchmark
- MSCI India Domestic & World HC 45 Index
- Short-term capital gains
- Returns taxed at 20% if you redeem before 1 year
- Long-term capital gains
- After 1 year, returns above ₹1.25 lakh in a financial year are taxed at 12.5%
Risk
Risk
What the riskometer means for this fund, and how its ratios sit against the category.
Very High
Your principal is treated as being at very high risk — typically small cap, sectoral and thematic equity schemes.
| Ratio | Fund | Category avg | Read as |
|---|---|---|---|
| Alpha | 2.20 | 0.74 | Return earned above what the benchmark alone would have given. Higher is better. |
| Beta | 0.66 | 0.93 | How hard the fund moves when the market moves. Under 1 is steadier than the market. |
| Sharpe | 1.10 | 1.05 | Return earned for each unit of total risk taken. Higher is better. |
| Sortino | 2.07 | 1.63 | Return earned for each unit of downside risk. Higher is better. |
| Std. deviation | 12.17 | 15.68 | How widely monthly returns have varied around their own average. Lower is steadier. |
| Average of 5 category peers | |||
Portfolio
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund portfolio
Portfolio as of 31 Aug 2026
Asset allocation
- Equity99.9%
- Debt0.0%
- Other0.1%
Market cap split
- Large63.0%
- Mid35.0%
- Small2.1%
- P/E
- 736.77
- P/B
- 99.38
Top holdings
| Holding | Sector | Weight | Value | 3M chg | 6M chg | 1Y chg |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Healthcare | 10.99% | ₹21.94 Cr | +11.42% | +11.25% | +10.84% |
| Divi's Laboratories Ltd. | Healthcare | 6.96% | ₹13.89 Cr | +5.27% | +5.17% | +5.19% |
| Eli Lilly And Co | Healthcare | 6.34% | ₹12.66 Cr | +6.50% | +6.01% | +5.01% |
| Apollo Hospitals Enterprise Ltd. | Healthcare | 5.51% | ₹11.00 Cr | +5.83% | +5.69% | +5.43% |
| Max Healthcare Institute Ltd. | Healthcare | 4.52% | ₹9.03 Cr | +4.97% | +5.73% | +6.36% |
| Torrent Pharmaceuticals Ltd. | Healthcare | 4.45% | ₹8.88 Cr | +3.46% | +3.46% | +2.99% |
| Cipla Ltd. | Healthcare | 4.38% | ₹8.74 Cr | +5.24% | +5.14% | +6.36% |
| Johnson & Johnson Ltd. | Healthcare | 4.37% | ₹8.73 Cr | +3.94% | +4.25% | +3.62% |
| Laurus Labs Ltd. | Healthcare | 4.14% | ₹8.25 Cr | +3.16% | +2.55% | +2.13% |
| Dr. Reddy's Laboratories Ltd. | Healthcare | 3.56% | ₹7.10 Cr | +4.68% | +4.71% | +5.21% |
| AbbVie Inc | Healthcare | 3.10% | ₹6.18 Cr | +2.79% | +2.91% | +3.16% |
| Lupin Ltd. | Healthcare | 3.08% | ₹6.14 Cr | +3.77% | +3.90% | +3.06% |
| Aurobindo Pharma Ltd. | Healthcare | 2.76% | ₹5.51 Cr | +2.47% | +2.15% | +1.90% |
| Fortis Healthcare Ltd. | Healthcare | 2.74% | ₹5.47 Cr | +3.01% | +3.12% | +3.17% |
| Merck & Co Inc (US) | Healthcare | 2.49% | ₹4.98 Cr | +2.14% | +2.20% | +1.79% |
| Glenmark Pharmaceuticals Ltd. | Healthcare | 2.15% | ₹4.30 Cr | +2.34% | +2.24% | +1.92% |
| Novartis AG | Healthcare | 1.90% | ₹3.80 Cr | +2.07% | +2.28% | +2.04% |
| Ipca Laboratories Ltd. | Healthcare | 1.70% | ₹3.38 Cr | +1.41% | +1.44% | +1.37% |
| Biocon Ltd. | Healthcare | 1.64% | ₹3.28 Cr | +1.71% | +1.41% | +1.32% |
| Amgen Inc. (USA) | Healthcare | 1.58% | ₹3.16 Cr | +1.32% | +1.48% | +1.31% |
| Thermo Fisher Scientific Inc. | Healthcare | 1.57% | ₹3.13 Cr | +1.34% | +1.37% | +1.58% |
| Mankind Pharma Ltd. | Healthcare | 1.54% | ₹3.07 Cr | +1.95% | +1.88% | +2.17% |
| Alkem Laboratories Ltd. | Healthcare | 1.37% | ₹2.74 Cr | +1.74% | +1.82% | +1.57% |
| Zydus Lifesciences Ltd. | Healthcare | 1.33% | ₹2.66 Cr | +1.43% | +1.25% | +1.75% |
| Gland Pharma Ltd. | Healthcare | 1.32% | ₹2.63 Cr | +1.10% | +0.91% | +0.98% |
| Abbott Laboratories | Healthcare | 1.31% | ₹2.62 Cr | +1.07% | +1.42% | +1.95% |
| Gilead Sciences Inc. (USA) | Healthcare | 1.24% | ₹2.48 Cr | +1.21% | +1.31% | +1.19% |
| Aster DM Quality Care Ltd. | Healthcare | 1.08% | ₹2.17 Cr | +1.12% | +1.03% | — |
| Novo Nordisk A/S - ADR | Healthcare | 1.00% | ₹1.99 Cr | +1.07% | +0.86% | +1.52% |
| Ajanta Pharma Ltd. | Healthcare | 0.97% | ₹1.93 Cr | +0.85% | +0.88% | +0.77% |
| Vertex Pharmaceuticals Inc. (USA) | Healthcare | 0.95% | ₹1.89 Cr | +0.82% | +0.90% | +0.85% |
| Danaher Corporation | Healthcare | 0.93% | ₹1.86 Cr | +0.84% | +0.95% | +1.13% |
| Intuitive Surgical Inc. (USA) | Healthcare | 0.91% | ₹1.82 Cr | +1.10% | +1.27% | +1.44% |
| Medtronic | Healthcare | 0.79% | ₹1.59 Cr | +0.69% | +0.89% | +1.01% |
| Stryker Corp | Healthcare | 0.76% | ₹1.52 Cr | +0.76% | +0.94% | +1.14% |
| Global Health Ltd. | Healthcare | 0.73% | ₹1.47 Cr | +0.63% | +0.62% | +0.78% |
| Glaxosmithkline Pharmaceuticals Ltd. | Healthcare | 0.72% | ₹1.43 Cr | +0.62% | +0.73% | +0.84% |
| Narayana Hrudayalaya Ltd. | Healthcare | 0.71% | ₹1.43 Cr | +0.89% | +0.88% | +0.89% |
| Regeneron Pharmaceuticals Inc | Healthcare | 0.57% | ₹1.13 Cr | +0.47% | +0.58% | +0.52% |
| Anthem Biosciences Ltd. | Healthcare | 0.48% | ₹0.96 Cr | — | — | — |
| Becton Dickinson And Co | Healthcare | 0.37% | ₹0.73 Cr | +0.30% | +0.36% | +0.46% |
| Agilent Technologies Inc | Healthcare | 0.30% | ₹0.59 Cr | +0.28% | +0.24% | +0.30% |
| Iqvia Holdings | Healthcare | 0.30% | ₹0.60 Cr | +0.22% | +0.21% | +0.28% |
| Water Corporation ORD SHS | Healthcare | 0.28% | ₹0.55 Cr | +0.11% | — | — |
| Others | Others | 0.11% | ₹0.24 Cr | +0.90% | +0.52% | +1.17% |
Sectors
Instruments
Recent changes
| Holding | From | To | Weight |
|---|---|---|---|
| Divi's Laboratories Ltd. | 6.07% | 6.96% | +0.89% |
| Lupin Ltd. | 3.48% | 3.08% | -0.40% |
| Max Healthcare Institute Ltd. | 4.89% | 4.52% | -0.37% |
| Cipla Ltd. | 4.69% | 4.38% | -0.31% |
| Sun Pharmaceutical Industries Ltd. | 11.30% | 10.99% | -0.31% |
| Merck & Co Inc (US) | 2.24% | 2.49% | +0.25% |
| Fortis Healthcare Ltd. | 2.93% | 2.74% | -0.19% |
| Apollo Hospitals Enterprise Ltd. | 5.69% | 5.51% | -0.18% |
| Torrent Pharmaceuticals Ltd. | 4.61% | 4.45% | -0.16% |
| Glenmark Pharmaceuticals Ltd. | 1.99% | 2.15% | +0.16% |
| Ipca Laboratories Ltd. | 1.54% | 1.70% | +0.16% |
| Gland Pharma Ltd. | 1.17% | 1.32% | +0.15% |
| Alkem Laboratories Ltd. | 1.52% | 1.37% | -0.15% |
| Aurobindo Pharma Ltd. | 2.61% | 2.76% | +0.15% |
| Amgen Inc. (USA) | 1.45% | 1.58% | +0.13% |
| Aster DM Quality Care Ltd. | 1.21% | 1.08% | -0.13% |
| Laurus Labs Ltd. | 4.02% | 4.14% | +0.12% |
| Gilead Sciences Inc. (USA) | 1.13% | 1.24% | +0.11% |
| Vertex Pharmaceuticals Inc. (USA) | 0.84% | 0.95% | +0.11% |
| Biocon Ltd. | 1.74% | 1.64% | -0.10% |
| Novartis AG | 1.99% | 1.90% | -0.09% |
| Eli Lilly And Co | 6.43% | 6.34% | -0.09% |
| Thermo Fisher Scientific Inc. | 1.49% | 1.57% | +0.08% |
| Glaxosmithkline Pharmaceuticals Ltd. | 0.64% | 0.72% | +0.08% |
| Johnson & Johnson Ltd. | 4.30% | 4.37% | +0.07% |
| Mankind Pharma Ltd. | 1.61% | 1.54% | -0.07% |
| Narayana Hrudayalaya Ltd. | 0.78% | 0.71% | -0.07% |
| Dr. Reddy's Laboratories Ltd. | 3.63% | 3.56% | -0.07% |
| Danaher Corporation | 0.87% | 0.93% | +0.06% |
| Novo Nordisk A/S - ADR | 1.06% | 1.00% | -0.06% |
| Intuitive Surgical Inc. (USA) | 0.87% | 0.91% | +0.04% |
| Anthem Biosciences Ltd. | 0.44% | 0.48% | +0.04% |
| Becton Dickinson And Co | 0.33% | 0.37% | +0.04% |
| Abbott Laboratories | 1.28% | 1.31% | +0.03% |
| Medtronic | 0.76% | 0.79% | +0.03% |
| Agilent Technologies Inc | 0.27% | 0.30% | +0.03% |
| Global Health Ltd. | 0.71% | 0.73% | +0.02% |
| Stryker Corp | 0.78% | 0.76% | -0.02% |
| Water Corporation ORD SHS | 0.26% | 0.28% | +0.02% |
| Others | 0.05% | 0.03% | -0.02% |
| Iqvia Holdings | 0.28% | 0.30% | +0.02% |
| Regeneron Pharmaceuticals Inc | 0.55% | 0.57% | +0.02% |
| AbbVie Inc | 3.09% | 3.10% | +0.01% |
| Ajanta Pharma Ltd. | 0.96% | 0.97% | +0.01% |
| Zydus Lifesciences Ltd. | 1.32% | 1.33% | +0.01% |
Compare
Similar funds
The rest of the category, so this fund’s numbers have something to sit against.
| Fund | AUM | Expense | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| Category average | ₹3,579 Cr | 2.19% | 27.3% | 17.7% | 20.1% |
 ICICI Prudential Healthcare Fund | ₹6,996 Cr | 2.07% | 14.5% | 14.2% | 19.4% |
 SBI Healthcare Opportunities Fund | ₹5,796 Cr | 1.99% | 33.1% | 19.9% | 22.2% |
 Mirae Asset Healthcare Fund | ₹3,555 Cr | 2.03% | 29.9% | 18.4% | 19.7% |
 UTI Healthcare Fund | ₹1,444 Cr | 2.21% | 30.4% | 19.1% | 21.1% |
 LIC MF Healthcare Fund | ₹103 Cr | 2.67% | 28.7% | 16.9% | 17.9% |
About
About this fund
The scheme’s own words, its benchmark and the people running it.
Investment objective
The scheme seeks to invest in stocks comprising of the MSCI India Domestic & World Healthcare 45 Index with the objective to provide investment returns that, before expenses, closely corresponds to the returns equivalent to the index, subject to tracking errors.
Fund managers
- Bhavesh JainMr. Jain is a MMS (Finance) from Mumbai University.Prior to joining Edelweiss Mutual Fund he was previously associated with Edelweiss Securities Limited as SGX Nifty Arbitrage Trader.
Tools
Return calculator
What ₹10,000 a month in this fund would have grown to over each period, based on its past returns.
₹
| Over the past | Total investment | Would’ve become | Growth | Returns |
|---|---|---|---|---|
| 6 months17.92% absolute | ₹60,000 | ₹70,752 | 17.92% | |
| 1 year24.96% annualised | ₹1,20,000 | ₹1,37,528 | 14.61% | |
| 3 years19.97% annualised | ₹3,60,000 | ₹4,95,762 | 37.71% | |
| 5 years13.95% annualised | ₹6,00,000 | ₹8,70,789 | 45.13% |
Returns for 1 year and longer are annualised (CAGR); 6-month figures are absolute. Past returns are not a forecast.
How this is calculated
Each monthly instalment grows at the fund’s annualised return ÷ 12 per month until the end of the period, the same formula as our SIP calculator.
The amount compounds once a year at the fund’s CAGR for that period, the same formula as our lumpsum calculator.
Questions
Frequently asked questions
The things people ask about this scheme.
What is the NAV of Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund?
The NAV of Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund is ₹24.18 as on 25 Sep 2026.
What is the expense ratio of Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund?
The expense ratio of Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund is 1.10% per year.
What is the minimum SIP amount for Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund?
You can start a SIP in Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund with ₹-1 a month.
What returns has Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund given?
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund has returned 25.2% over 1 year, 17.1% over 3 years and 17.8% over 5 years (annualised).
Is there a lock-in or exit load on Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund?
Lock-in: None. Exit load: 0%.
How risky is Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund?
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund is rated Very High on the SEBI riskometer and belongs to the Sectoral-Pharma category.
Which fund house manages Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund?
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund is managed by Edelweiss Mutual Fund, which runs 59 schemes with ₹1,95,092 Cr under management.